The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence ...

Magrolimab triple therapy falls short of expectations in a study of previously untreated acute myeloid leukemia.

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The disparities, undeniable.

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over ...

Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of ...

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis ...